Guggenheim reiterates buy on ANI Pharmaceuticals, maintains $124 target
Guggenheim analyst Vamil Divan has reiterated a Buy rating for ANI Pharmaceuticals, maintaining a price target of $124. The endorsement underscores confidence in the company's stock performance potential.
*this image is generated using AI for illustrative purposes only.
Guggenheim analyst Vamil Divan has reaffirmed a Buy rating for ANI Pharmaceuticals, maintaining a price target of $124. The endorsement underscores confidence in the company's stock performance potential.
Analyst Rating and Target
The rating reiteration comes as the firm assesses the current valuation and future prospects of ANI Pharmaceuticals. The $124 price target provides a specific benchmark for investors regarding the stock's anticipated trajectory.
| Metric | Value |
|---|---|
| Rating | Buy |
| Price Target | $124 |
| Coverage Firm | Guggenheim |
| Analyst | Vamil Divan |
What specific catalysts does Guggenheim anticipate will drive ANI Pharmaceuticals toward the $124 price target?
How might upcoming product launches or pipeline advancements influence ANI Pharmaceuticals' market position in the near term?
What are the potential risks or market headwinds that could hinder ANI Pharmaceuticals from achieving the projected growth?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
